Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers

NCT02220647 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Linagliptin/Metformin FDC
DRUG: Linagliptin
DRUG: Metformin

Sponsor

Boehringer Ingelheim